Assessment of High-Sensitive Methods for the Detection of EGFR Mutations in Circulating Free Tumor DNA from NSCLC Patients

References

• Herbst RS , HeymachJV , LippmanSM . Lung cancer . N. Engl. J. Med.359 ( 13 ), 1367 – 1380 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Garraway LA . Genomics-driven oncology: framework for an emerging paradigm . J. Clin. Oncol.31 ( 15 ), 1806 – 1814 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Comprehensive molecular profiling of lung adenocarcinoma . Nature511 ( 7511 ), 543 – 550 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• De Luca A , NormannoN . Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer . Curr. Drug Targets11 ( 7 ), 851 – 864 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Rossi A , PasqualeR , EspositoC , NormannoN . Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?Cancer Treat. Rev.39 ( 5 ), 489 – 497 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gazdar AF . Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors . Oncogene28 ( Suppl. 1 ), S24 – 31 ( 2009 ).
   PubMedGoogle Scholar
• Maemondo M , InoueA , KobayashiKet al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR . N. Engl. J. Med.362 ( 25 ), 2380 – 2388 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS , YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial . Lancet Oncol.11 ( 2 ), 121 – 128 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL , ThongprasertSet al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N. Engl. J. Med.361 ( 10 ), 947 – 957 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Marchetti A , NormannoN , PintoCet al. Recommendations for mutational analysis of EGFR in lung carcinoma . Pathologica102 ( 3 ), 119 – 126 ( 2010 ).
   PubMedGoogle Scholar
• Reck M , PopatS , ReinmuthN , De RuysscherD , KerrKM , PetersS . Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up . Ann. Oncol.25 ( Suppl. 3 ), iii27 – iii39 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fleischhacker M , SchmidtB . Cell-free DNA resuscitated for tumor testing . Nat. Med.14 ( 9 ), 914 – 915 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Murtaza M , DawsonSJ , TsuiDWet al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA . Nature497 ( 7447 ), 108 – 112 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr , BardelliA . Liquid biopsies: genotyping circulating tumor DNA . J. Clin. Oncol.32 ( 6 ), 579 – 586 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Luke JJ , OxnardGR , PaweletzCPet al. Realizing the potential of plasma genotyping in an age of genotype-directed therapies . J. Natl Cancer Inst.106 ( 8 ), ( 2014 ).
   PubMedGoogle Scholar
• Douillard JY , OstorosG , CoboMet al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status . J. Thorac. Oncol.9 ( 9 ), 1345 – 1353 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Douillard JY , OstorosG , CoboMet al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a Phase-IV, open-label, single-arm study . Br. J. Cancer110 ( 1 ), 55 – 62 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rosell R , CarcerenyE , GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial . Lancet Oncol.13 ( 3 ), 239 – 246 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Rosell R , MoranT , QueraltCet al. Screening for epidermal growth factor receptor mutations in lung cancer . N. Engl. J. Med.361 ( 10 ), 958 – 967 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Nagai Y , MiyazawaH , Huqunet al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp . Cancer Res.65 ( 16 ), 7276 – 7282 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Iressa. EPAR – Product Information : www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf .
   Google Scholar
• Roma C , EspositoC , RachiglioAMet al. Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology . Biomed. Res. Int.2013 ( 385087 ), 9 ( 2013 ).
   Google Scholar
• Goto K , IchinoseY , OheYet al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer . J. Thorac. Oncol.7 ( 1 ), 115 – 121 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Higgins MJ , JelovacD , BarnathanEet al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood . Clin. Cancer Res.18 ( 12 ), 3462 – 3469 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Maheswaran S , SequistLV , NagrathSet al. Detection of mutations in EGFR in circulating lung-cancer cells . N. Engl. J. Med.359 ( 4 ), 366 – 377 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Morabito A , SandomenicoC , CostanzoRet al. Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib . J. Thorac. Oncol.7 ( 11 ), e27 – e28 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Sorensen BS , WuL , WeiWet al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib . Cancer120 ( 24 ), 3896 – 3901 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Normanno N , RachiglioAM , RomaCet al. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities . J. Cell Biochem.114 ( 3 ), 514 – 524 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Luo J , ShenL , ZhengD . Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis . Sci. Rep.4 , 6269 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Nakamura T , Sueoka-AraganeN , IwanagaKet al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA . J. Thorac. Oncol.6 ( 10 ), 1639 – 1648 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Taniguchi K , UchidaJ , NishinoKet al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas . Clin. Cancer Res.17 ( 24 ), 7808 – 7815 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Oxnard GR , PaweletzCP , KuangYet al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA . Clin. Cancer Res.20 ( 6 ), 1698 – 1705 ( 2014 ).
   PubMed Web of Science ®Google Scholar